All In Biotech

Drug Trial Radar · NCT07927218

Study of Food Effects of VV261 Tablets in Healthy Trial Participants

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Nov 9, 2026

Primary completion

Dec 30, 2026

Study completion Jan 30, 2027

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, open-label, three-cycle, self-cross-over study on human pharmacokinetic characteristics under fasting, standard meal, and high-fat meal conditions.

Conditions

  • Severe Fever With Thrombocytopenia Syndrome

Interventions

  • VV261Drug

    A group:600 mg VV261, following an overnight fast of at least 10 hours for Period 1 ;600 mg VV261, administered 30 minutes after the start of a Standard meal for Period 2 ; 600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 3;

  • VV261Drug

    B group:600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 1 ; 600 mg VV261, following an overnight fast of at least 10 hours for Period 2 ; 600 mg VV261, administered 30 minutes after the start of a Standard meal for Period 3;

  • VV261Drug

    C group:administered 30 minutes after the start of a Standard meal for Period 1;600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 2 ; 600 mg VV261, following an overnight fast of at least 10 hours for Period 3 ;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: Baseline to 96 hours after the last administration
  2. TmaxTime frame: Baseline to 96 hours after the last administration
  3. AUC0-tTime frame: Baseline to 96 hours after the last administration
  4. AUC0-∞Time frame: Baseline to 96 hours after the last administration
  5. t1/2Time frame: Baseline to 96 hours after the last administration
  6. CL/FTime frame: Baseline to 96 hours after the last administration
  7. mean Resident TimeTime frame: Baseline to 96 hours after the last administration
  8. Vd/FTime frame: Baseline to 96 hours after the last administration
  9. Incidence of Treatment-Emergent Adverse EventsTime frame: Baseline to 7days after the last administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.